Find trials
Search tips

Florida Cerebrovascular Disease Biorepository and Genomics Center

Overview

About this study

The aim of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida. The Center will collect and store detailed phenotypic information, DNA, and other biofluids on affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Affected and unaffected family members of diverse cerebrovascular conditions, including, but not limited to:

  • ischemic stroke;
  • transient ischemic attack (TIA);
  • intracerebral hemorrhage (ICH);
  • aneurysmal subarachnoid hemorrhage (aSAH);
  • vascular dementia (VAD);
  • anoxic brain injury;
  • unruptured intracranial aneurysm (UIA);
  • cavernous malformation;
  • arteriovenous malformations (AVM);
  • carotid and vertebral arterial dissections;
  • ymptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis;
  • non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH);
  • cerebral venous thrombosis (CVT);
  • moyamoya disease;
  • fibrosmuscular dysplasia (FMD);
  • non-traumatic, angiography-negative subarachnoid hemorrhage;
  • leukoaraiosis;
  • arteriovenous fistula;
  • reversible cerebral vasoconstriction syndrome (RCVS);
  • CADASIL.

Exclusion Criteria:

All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study:

  • Human immunodeficiency virus (HIV);
  • Any viral hepatitis;
  • West Nile virus (WNV);
  • Influenza virus;
  • Tuberculosis (TB);
  • Any bacteremia;
  • Any fungemia;
  • Any prionopathy.

Eligibility last updated 8/3/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

James Meschia, M.D.

Open for enrollment

Contact information:

Maria Caruso

(904) 953-7897

Caruso.Maria@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20536360

Mayo Clinic Footer